日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer

新型 CHD1L 抑制剂作为癌症治疗策略的验证

期刊:Biomedicine & Pharmacotherapy
影响因子:6.9
doi:10.1016/j.biopha.2023.116037
Sophia Clune, Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, Jeffrey T Kearns, Timothy Kellett, Damilola Caleb Akintayo, Uday B Kompella, Daniel V LaBarbera
肿瘤
发表日期：2024
文献求助 收藏

CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models

CHD1L 抑制剂 OTI-611 与化疗协同作用，增强抗肿瘤疗效并延长结直肠癌小鼠模型的生存期

期刊:International Journal of Molecular Sciences
影响因子:0.7
doi:10.3390/ijms252313160
Rita Sala, Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A Pike, Qiong Zhou, Wells A Messersmith, Daniel V LaBarbera
肿瘤
肠癌
发表日期：2024
文献求助 收藏

CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos

CHD1L 调节乳腺癌细胞存活，OTI-611 抑制该基因可阻碍 DNA 损伤反应并诱导 PARthanatos

期刊:International Journal of Molecular Sciences
影响因子:0.7
doi:10.3390/ijms25168590
Rita Sala, Hector Esquer, Timothy Kellett, Jeffrey T Kearns, Paul Awolade, Qiong Zhou, Daniel V LaBarbera
肿瘤
乳腺癌
肿瘤细胞
发表日期：2024
文献求助 收藏

Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L

首个致癌 CHD1L 抑制剂的设计、合成及生物学评价

期刊:Journal of Medicinal Chemistry
影响因子:6.8
doi:10.1021/acs.jmedchem.1c01778
Brett J Prigaro, Hector Esquer, Qiong Zhou, Laura A Pike, Paul Awolade, Xin-He Lai, Adedoyin D Abraham, Joshua M Abbott, Brock Matter, Uday B Kompella, Wells A Messersmith, Daniel L Gustafson, Daniel V LaBarbera
肿瘤
HTRF
发表日期：2022
文献求助 收藏